Evaluation – Talk Bio

Trump Administration Pauses Pharmaceutical Tariffs to Negotiate Industry Agreements

1 week ago talkbio0Tagged branded drugs, domestic manufacturing, drug price, Evaluation, patented drugs, pharmaceutical tariffs, Sectioning technique, tariff pause, Transplant Registry Unified Management Program

Trump; pharmaceutical tariffs; tariff pause; drug pricing; domestic manufacturing; Section 232 investigation; branded drugs; patented drugs

Trump Administration Launches Tariff Probe into Medtech and Pharmaceutical Industries

2 weeks ago talkbio0Tagged Evaluation, Manufacturing, Medical Devices, medtech industry, National Security, pharmaceutical imports, Sectioning technique, semiconductor tariffs, supply chain, tariffs, Transplant Registry Unified Management Program

Trump administration; tariffs; medtech industry; pharmaceutical imports; Section 232 investigation; semiconductor tariffs; national security; supply chain; manufacturing; medical devices

Trump Administration May Exempt Some Pharma Products from Future Tariffs in Trade Policy Shift

1 month ago talkbio0Tagged active pharmaceutical ingredients, Evaluation, generic pharmaceuticals, pharmaceutical tariffs, reciprocal tariffs, Secretary, Sectioning technique, tariff exemptions, trade policy, Trump administration

pharmaceutical tariffs; tariff exemptions; Trump administration; Section 232 investigation; trade policy; reciprocal tariffs; generic pharmaceuticals; active pharmaceutical ingredients; commerce secretary authority

UK Pharma Trade Group Calls for Overhaul of Government’s Life Sciences Investment Evaluation and Medicines Pricing Schemes

1 month ago talkbio0Tagged ABPI, Biological Science Disciplines, Evaluation, government review, innovation, Investments, Nance-Horan syndrome, pharma trade group, Pricing, statutory scheme, UK, valproic acid glucuronide

UK life sciences; ABPI; VPAG; pharma trade group; investment evaluation; medicines pricing; government review; NHS; innovation; statutory scheme

Trump Locks in 15% Pharmaceutical Tariff Rate for EU, Generic Drugs Exempted

2 months ago talkbio0Tagged 15%, brand-name drugs, EU, Evaluation, Generic Drugs, Sectioning technique, tariff, tariff exemption, TNFRSF19 gene, transatlantic trade, Trump administration

15% tariff; pharmaceuticals; EU; Trump administration; generic drugs; trade deal; tariff exemption; brand-name drugs; transatlantic trade; Section 232 investigation

Trump’s Pharmaceutical Tariffs Materialize in New US-EU Trade Deal

2 months ago talkbio0Tagged 15%, European (ethnic group), Evaluation, pharmaceutical tariffs, Sectioning technique, tariff, trade agreement, Transplant Registry Unified Management Program, U.S., Union, US-EU

Trump; pharmaceutical tariffs; US-EU trade deal; 15% tariff; Section 232 investigation; European Union exports; trade agreement

FDA Investigates Patient Deaths Linked to Sarepta’s Elevidys Gene Therapy for Duchenne Muscular Dystrophy

4 months ago talkbio0Tagged ELEVIDYS, Evaluation, gene therapy, Liver, Liver Failure, Acute, Muscular Dystrophy, Duchenne, patient deaths, regulatory, Toxicity aspects, Unable to walk (finding), United States Food and Drug Administration

FDA; Sarepta; Elevidys; Duchenne muscular dystrophy; gene therapy; patient deaths; acute liver failure; liver toxicity; regulatory investigation; non-ambulatory patients

OpenAI Debuts HealthBench Dataset to Evaluate AI Models in Real-World Medical Scenarios

5 months ago talkbio0Tagged AI safety, Artificial Intelligence, Evaluation, HealthBench, healthcare benchmark, language models, medical AI, open-source dataset, OpenAI, Physicians, realistic medical scenarios, rubrics

OpenAI; HealthBench; AI healthcare benchmark; large language models; medical AI evaluation; physician rubrics; realistic medical scenarios; AI safety; open-source dataset

Citing tariffs, Illumina slashes guidance, confirms SEC’s Grail investigation is closed

5 months ago talkbio0Tagged Acquisition (action), Divestiture, Evaluation, Grail, Illumina, SEC

Illumina, SEC, Acquisition (action), Evaluation, divestiture, Grail

FDA delays decision date on Cytokinetics’ heart drug to year-end in unusual safety program back-and-forth

5 months ago talkbio0Tagged Cytokinetics, Deferred, Evaluation, Extension, Hypertrophic obstructive cardiomyopathy, Mitigation Strategy, oHCM, PDUFA, Regulatory Setback, REMS, Risk, United States Food and Drug Administration

Cytokinetics, aficamten, FDA delay, PDUFA date extension, hypertrophic obstructive cardiomyopathy (oHCM), Risk Evaluation and Mitigation Strategy (REMS), regulatory setback